US2020248249A1PendingUtilityA1

Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna

Assignee: UNIV LELAND STANFORD JUNIORPriority: Apr 7, 2016Filed: Apr 14, 2020Published: Aug 6, 2020
Est. expiryApr 7, 2036(~9.7 yrs left)· nominal 20-yr term from priority
C12Q 1/6869C12N 15/00C12Q 1/6806C12Q 1/6886C12Q 2600/154C12Q 2563/185C12Q 2545/101C40B 50/04C12Q 1/6855C12Q 2525/191C40B 70/00C40B 40/08
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein is a method of sequencing hydroxymethyated cell-free DNA. In some embodiments, the method comprises adding an affinity tag to only hydroxymethyated DNA molecules in a sample of cfDNA, enriching for the DNA molecules that are tagged with the affinity tag; and sequencing the enriched DNA molecules.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A spike-in control composition that comprises:
 (a) a first amplicon synthesized from a mixture comprising dATP, dGTP, dTTP, and dCTP;   (b) a second amplicon synthesized from a mixture comprising dATP, dGTP, dTTP, and dmCTP; and   (c) a third amplicon synthesized from a mixture comprising dATP, dGTP, dTTP, and dhmCTP.   
     
     
         2 . The composition of  claim 1 , wherein the third amplicon is synthesized from a mixture comprising dATP, dGTP, dTTP, dCTP, and dhmCTP. 
     
     
         3 . The composition of  claim 2 , wherein the first, second, and third amplicons are nonoverlapping.

Join the waitlist — get patent alerts

Track US2020248249A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.